Suppr超能文献

设计、合成和生物评价作为腺苷 A 受体配体的托扎丹南类似物。

Design, synthesis and biological evaluation of Tozadenant analogues as adenosine A receptor ligands.

机构信息

Institute of Neuroscience and Medicine, Nuclear Chemistry (INM-5), Germany; University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Radiochemistry and Experimental Molecular Imaging, Kerpener Straße 62, 50937, Köln, Germany; Forschungszentrum Jülich GmbH, Germany.

Institute of Neuroscience and Medicine, Nuclear Chemistry (INM-5), Germany; Forschungszentrum Jülich GmbH, Germany.

出版信息

Eur J Med Chem. 2021 Mar 15;214:113214. doi: 10.1016/j.ejmech.2021.113214. Epub 2021 Jan 30.

Abstract

With the aim to obtain potent adenosine A receptor (AR) ligands, a series of eighteen derivatives of 4-hydroxy-N-(4-methoxy-7-morpholin-4-yl-1,3-benzo[d]thiazol-2-yl)-4-methylpiperidine-1-carboxamide (SYN-115, Tozadenant) were designed and synthesized. The target compounds were obtained by a chemical building block principle that involved reaction of the appropriate aminobenzothiazole phenyl carbamates with either commercially available or readily synthesized functionalized piperidines. Their affinity and subtype selectivity with regard to human adenosine A-and A receptors were determined using radioligand binding assays. K values for human AR ranged from 2.4 to 38 nM, with more than 120-fold selectivity over A receptors for all evaluated compounds except 13k which had a K of 361 nM and 18-fold selectivity. The most potent fluorine-containing derivatives 13e, 13g and 13l exhibited K values of 4.9 nM, 3.6 nM and 2.8 nM for the human AR. Interestingly, the corresponding values for rat AR were found to be four to five times higher. Their binding to AR was further confirmed by radiolabeling with F and in vitro autoradiography in rat brain slices, which showed almost exclusive striatal binding and complete displacement by the AR antagonist ZM 241385. We conclude that these compounds represent potential candidates for the visualization of the A receptor and open pathways to novel therapeutic treatments of neurodegenerative disorders or cancer.

摘要

为了获得强效的腺苷 A 受体 (AR) 配体,设计并合成了一系列十八个 4-羟基-N-(4-甲氧基-7-吗啉-4-基-1,3-苯并[d]噻唑-2-基)-4-甲基哌啶-1-甲酰胺(SYN-115,托扎丹特)的衍生物。目标化合物是通过化学砌块原理获得的,涉及用合适的氨基苯并噻唑苯氨基甲酸酯与市售或易于合成的功能化哌啶反应。使用放射性配体结合测定法测定了它们与人腺苷 A 和 A 受体的亲和力和亚型选择性。人 AR 的 K 值范围为 2.4 至 38 nM,除了 K 值为 361 nM 且选择性为 18 倍的 13k 外,所有评估的化合物对 A 受体的选择性均超过 120 倍。最有效的含氟衍生物 13e、13g 和 13l 对人 AR 的 K 值分别为 4.9 nM、3.6 nM 和 2.8 nM。有趣的是,发现大鼠 AR 的相应值高四倍至五倍。用 F 进行放射性标记和在大鼠脑切片中的体外放射自显影进一步证实了它们与 AR 的结合,这表明它们几乎只与纹状体结合,并且被 AR 拮抗剂 ZM 241385 完全置换。我们得出的结论是,这些化合物代表了可视化 A 受体的潜在候选物,并为治疗神经退行性疾病或癌症的新型治疗方法开辟了途径。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验